PMID- 24573383
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20211021
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 28
IP  - 9
DP  - 2014 Sep
TI  - MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in 
      Waldenstrom's Macroglobulinemia.
PG  - 1799-803
LID - 10.1038/leu.2014.88 [doi]
AB  - Waldenstrom's Macroglobulinemia (WM) is a rare disease of the elderly with a 
      median age of 63-68 years at diagnosis. Despite recent progress in biological 
      insights and therapeutics, WM remains clinically challenging to diagnose and is 
      difficult to manage with significant morbidity and lack of established curative 
      therapies. Recently, the use of whole-genome sequencing has helped to identify a 
      highly recurrent somatic mutation, myeloid differentiation factor 88 [MYD88] 
      L265P in WM. This has fueled major interest in the field and as newer evidence 
      accumulates, it is clear that that discovery of MYD88 L265P mutation may 
      represent an important breakthrough in understanding the pathogenesis of WM and 
      lymphoproliferative disorders. Recent scientific work in this field has also 
      guided the identification of new targets such as CXCR4 and PI3K-delta that may 
      have major implications in the future treatment of WM. This review discusses the 
      role of MYD88 L265P mutations as well as targets beyond MYD88 in the setting of 
      pathogenesis and development of future rational therapeutic trials focusing on 
      patients diagnosed with WM.
FAU - Landgren, O
AU  - Landgren O
AD  - Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National 
      Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
FAU - Tageja, N
AU  - Tageja N
AD  - Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National 
      Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Review
DEP - 20140227
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Humans
MH  - *Mutation
MH  - Myeloid Differentiation Factor 88/*genetics/physiology
MH  - NF-kappa B/physiology
MH  - Prognosis
MH  - Waldenstrom Macroglobulinemia/diagnosis/etiology/*genetics/therapy
EDAT- 2014/02/28 06:00
MHDA- 2014/11/02 06:00
CRDT- 2014/02/28 06:00
PHST- 2013/12/16 00:00 [received]
PHST- 2014/01/13 00:00 [revised]
PHST- 2014/01/15 00:00 [accepted]
PHST- 2014/02/28 06:00 [entrez]
PHST- 2014/02/28 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
AID - leu201488 [pii]
AID - 10.1038/leu.2014.88 [doi]
PST - ppublish
SO  - Leukemia. 2014 Sep;28(9):1799-803. doi: 10.1038/leu.2014.88. Epub 2014 Feb 27.